Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

EXCEPTIONAL CASE REPORTS

REVIEW ARTICLE

CLINICAL TRIALS AND OBSERVATIONS

Meletios Dimopoulos,for the ASPEN investigators,Ramon Garcia Sanz,for the ASPEN investigators,Hui-Peng Lee,for the ASPEN investigators,Marek Trneny,for the ASPEN investigators,Marzia Varettoni,for the ASPEN investigators,Stephen Opat,for the ASPEN investigators,Shirley D'Sa,for the ASPEN investigators,Roger G. Owen,for the ASPEN investigators,Gavin Cull,for the ASPEN investigators,Stephen Mulligan,for the ASPEN investigators,Jaroslaw Czyz,for the ASPEN investigators,Jorge J. Castillo,for the ASPEN investigators,Marina Motta,for the ASPEN investigators,Tanya Siddiqi,for the ASPEN investigators,Mercedes Gironella Mesa,for the ASPEN investigators,Miquel Granell Gorrochategui,for the ASPEN investigators,Dipti Talaulikar,for the ASPEN investigators,Pier Luigi Zinzani,for the ASPEN investigators,Elham Askari,for the ASPEN investigators,Sebastian Grosicki,for the ASPEN investigators,Albert Oriol,for the ASPEN investigators,Simon Rule,for the ASPEN investigators,Janusz Kloczko,for the ASPEN investigators,Alessandra Tedeschi,for the ASPEN investigators,Christian Buske,for the ASPEN investigators,Veronique Leblond,for the ASPEN investigators,Judith Trotman,for the ASPEN investigators,Wai Y. Chan,for the ASPEN investigators,Jan Michel,for the ASPEN investigators,Jingjing Schneider,for the ASPEN investigators,Ziwen Tan,for the ASPEN investigators,Aileen Cohen,for the ASPEN investigators,Jane Huang,for the ASPEN investigators,Constantine S. Tam,for the ASPEN investigators

HEALTH SERVICES AND OUTCOMES

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

Irena Misiewicz-Krzeminska,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Cristina de Ramón,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Luis A. Corchete,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Patryk Krzeminski,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Elizabeta A. Rojas,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Isabel Isidro,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Ramón García-Sanz,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Joaquín Martínez-López,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Albert Oriol,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Joan Bladé,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Juan-José Lahuerta,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Jesús San Miguel,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Laura Rosiñol,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,María-Victoria Mateos,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups,Norma C. Gutiérrez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatías Malignas Cooperative Study Groups
Frits van Rhee,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Eric Oksenhendler,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Gordan Srkalovic,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Peter Voorhees,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Megan Lim,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Angela Dispenzieri,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Makoto Ide,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Sophia Parente,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Stephen Schey,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Matthew Streetly,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Raymond Wong,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,David Wu,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Ivan Maillard,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Joshua Brandstadter,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Nikhil Munshi,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Wilbur Bowne,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Kojo S. Elenitoba-Johnson,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Alexander Fössa,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Mary Jo Lechowicz,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Shanmuganathan Chandrakasan,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Sheila K. Pierson,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Amy Greenway,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Sunita Nasta,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Kazuyuki Yoshizaki,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Razelle Kurzrock,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Thomas S. Uldrick,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Corey Casper,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,Amy Chadburn,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board,David C. Fajgenbaum,on behalf of the Castleman Disease Collaborative Network Scientific Advisory Board

MYELOID NEOPLASIA

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

VASCULAR BIOLOGY

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals